Cogent Biosciences (NASDAQ:COGT - Free Report) had its price objective upped by HC Wainwright from $12.00 to $22.00 in a report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the technology company's stock. HC Wainwright also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($2.93) EPS.
A number of other equities analysts have also issued reports on COGT. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. Robert W. Baird increased their price objective on Cogent Biosciences from $7.00 to $9.00 and gave the stock a "neutral" rating in a report on Tuesday. Leerink Partners increased their price objective on Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a report on Monday. Guggenheim reissued a "buy" rating and issued a $17.00 price objective on shares of Cogent Biosciences in a report on Tuesday. Finally, Wedbush reissued a "neutral" rating and issued a $10.00 price objective on shares of Cogent Biosciences in a report on Monday, June 30th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.
Check Out Our Latest Report on Cogent Biosciences
Cogent Biosciences Stock Performance
Shares of NASDAQ:COGT traded up $0.13 during trading on Tuesday, hitting $10.98. The company's stock had a trading volume of 3,386,326 shares, compared to its average volume of 1,570,620. Cogent Biosciences has a fifty-two week low of $3.72 and a fifty-two week high of $12.61. The stock's 50-day moving average price is $6.54 and its two-hundred day moving average price is $6.84. The company has a market capitalization of $1.25 billion, a PE ratio of -5.97 and a beta of 1.88.
Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04. On average, equities analysts predict that Cogent Biosciences will post -2.42 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cogent Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its stake in shares of Cogent Biosciences by 14.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company's stock worth $5,924,000 after acquiring an additional 124,069 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Cogent Biosciences by 3.9% during the 1st quarter. Rhumbline Advisers now owns 130,458 shares of the technology company's stock worth $781,000 after acquiring an additional 4,877 shares in the last quarter. Strs Ohio bought a new stake in shares of Cogent Biosciences during the 1st quarter worth $36,000. Jane Street Group LLC boosted its stake in shares of Cogent Biosciences by 66.2% during the 1st quarter. Jane Street Group LLC now owns 123,822 shares of the technology company's stock worth $742,000 after acquiring an additional 49,338 shares in the last quarter. Finally, Woodline Partners LP boosted its stake in shares of Cogent Biosciences by 175.2% during the 1st quarter. Woodline Partners LP now owns 1,687,540 shares of the technology company's stock worth $10,108,000 after acquiring an additional 1,074,375 shares in the last quarter.
Cogent Biosciences Company Profile
(
Get Free Report)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Recommended Stories
Before you consider Cogent Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.
While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
